Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price target lowered by equities research analysts at Cantor Fitzgerald from $103.00 to $33.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 24.39% from the stock’s previous close.
Several other research firms have also recently issued reports on RARE. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Morgan Stanley raised their target price on Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the stock an “overweight” rating in a research report on Friday, August 21st. HC Wainwright cut their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday. JPMorgan Chase & Co. cut shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $36.00 target price on the stock. in a research note on Thursday. Finally, Guggenheim cut their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.53.
Get Our Latest Stock Analysis on RARE
Ultragenyx Pharmaceutical Stock Performance
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The firm had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same quarter in the previous year, the business earned ($1.17) earnings per share. The company’s quarterly revenue was up 28.5% on a year-over-year basis. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post -3.97 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the transaction, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their position. The disclosure for this sale is available in the SEC filing. 5.20% of the stock is owned by insiders.
Institutional Trading of Ultragenyx Pharmaceutical
Hedge funds and other institutional investors have recently made changes to their positions in the business. Corient Private Wealth LP raised its position in shares of Ultragenyx Pharmaceutical by 7.3% in the 2nd quarter. Corient Private Wealth LP now owns 146,493 shares of the biopharmaceutical company’s stock valued at $4,891,000 after purchasing an additional 9,949 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at about $1,036,000. California State Teachers Retirement System increased its position in shares of Ultragenyx Pharmaceutical by 3,137.6% in the second quarter. California State Teachers Retirement System now owns 3,388,117 shares of the biopharmaceutical company’s stock valued at $113,129,000 after buying an additional 3,283,467 shares in the last quarter. denkapparat Operations GmbH acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth $230,000. Finally, Nykredit A S acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $154,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Featured Articles
- Five stocks we like better than Ultragenyx Pharmaceutical
- Enova’s Earnings Surge Meets a Valuation Test
- SLB’s Kelvion Deal Could Change How Investors Value the Oilfield Giant
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
